T-CURX participates in an € 11 M EU Innovative Medicines Initiative (IMI) grant "imSAVAR" as SME partner, a consortium with 26 partners from academia and industry
Today, it is announced, that T-CURX is a small-medium-sized-entity (SME) Partner and beneficiary in the € 11 Mio EU Innovative Medicines Initiative (IMI) grant "imSAVAR", including 9 EFPIA companies (European Federation of Pharmaceutical Industries and Associations), 13 academic partners, 4 European SMEs, and 1 U.S.-based associated partners.
The vision of imSAVAR (Immune Safety Avatar) is to develop a platform for integrated non-clinical assessments of safety and efficacy by immunomodulatory therapy. The aim is to develop a standard for integrated nonclinical safety overviews for immune-modulatory investigational new drugs (IND) and clinical trial applications (CTA).
The resulting platform will improve the prediction of the transferability of safety and efficacy of immunomodulators from pre-clinical models to first-in-human (FiH) studies. This joint effort of the private sector, pharma, regulators, and technology providers not only benefits the field of immune safety evaluation, but will also generate various opportunities for European businesses as well as foster the meaningful engagement of multiple stakeholders including patients and regulators.